Prestige Consumer Healthcare Inc. (PBH) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 1 fund adding versus the previous quarter. Latest close $50.62 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Ariel Investments · Maverick Capital — 2 tracked funds hold PBH. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Ariel Investments | 2.29% | 4,868,711 | ADDED (+13.9%) Q3 filed Nov 13 |
| Maverick Capital | 0.02% | 50,975 | NEW Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +0.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 315 of 8,857 filers |
| Long-only filers among them | 315 |
| Change vs 2026 Q1 | -27 net · 303 entered · 330 exited |
| Shares reported, all filers | 53,533,073 |
| Reported value, all filers | $2.5B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2026 | $1.1B |
| Net income · FY2026 | $190.3M |
| Total assets · FY2026 | $3.5B |
| Shares outstanding | 47,374,522 |
| Market cap (at latest close) | $2.4B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 3,962,178 |
| Share of shares outstanding | 8.36% |
| Days to cover | 7.25 |
Shares short at recent settlements — Jul 31, 2026: 3.8M · Aug 14, 2026: 4.3M · Aug 31, 2026: 4.6M · Sep 15, 2026: 4.8M · Sep 30, 2026: 4.6M · Oct 15, 2026: 4.0M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 1 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 3K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 1.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| May 11, 2026 | Zerillo Jeffrey | Officer | 351 | $18.4K | May 11, 2026 | SEC filing |
| May 7, 2026 | Zerillo Jeffrey | Officer | 305 | $16.6K | May 7, 2026 | SEC filing |
| May 6, 2026 | Zerillo Jeffrey | Officer | 1,207 | $66.4K | May 6, 2026 | SEC filing |
| May 5, 2026 | Zerillo Jeffrey | Officer | 346 | $19.1K | May 5, 2026 | SEC filing |
| Feb 11, 2026 | Zerillo Jeffrey | Officer | 1,000 | $65.9K | Feb 11, 2026 | SEC filing |
| Dec 1, 2025 | Zerillo Jeffrey | Officer | 281 | $16.9K | Dec 1, 2025 | SEC filing |
| Nov 28, 2025 | Zerillo Jeffrey | Officer | 719 | $43.1K | Nov 28, 2025 | SEC filing |
| Nov 25, 2025 | BYOM JOHN E | Director | 3,000 | $178.1K | Nov 25, 2025 | SEC filing |
| Mar 10, 2025 | Fritz Mary Beth | Officer | 1,678 | $151.0K | Mar 10, 2025 | SEC filing |
| Mar 3, 2025 | Fritz Mary Beth | Officer | 6,297 | $537.7K | Mar 3, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Ariel Investments, LLC | SC 13G/A | 4,868,711 | 10.3% | Jun 30, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 2,454,974 | 5.2% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Portfolio Management | SC 13G | 2,826,536 | 6.0% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 13, 2026 | Ariel Investments, LLC | SC 13G/A | 4,102,497 | 8.5% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | Ariel Investments, LLC | SC 13G | 3,594,959 | 7.3% | Sep 30, 2025 | SEC filing |
| Aug 13, 2025 | Ariel Investments, LLC | SC 13G/A | 2,202,327 | 4.5% | Jun 30, 2025 | SEC filing |
| Apr 30, 2025 | BlackRock, Inc. | SC 13G/A | 7,524,587 | 15.2% | Mar 31, 2025 | SEC filing |
| Feb 7, 2025 | Macquarie Group Limited | SC 13G/A | 2,309,017 | 4.7% | Dec 31, 2024 | SEC filing |
| Jan 23, 2025 | Dimensional Fund Advisors LP | SC 13G/A | 2,907,066 | 5.9% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Financial Screens
· Greenblatt Magic Formula — High earnings yield and high return on capital together
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Deep Value (Templeton) — Stocks that are cheap against both earnings and assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Key figures
· Greenblatt Magic Formula — Earnings yield: 7.9% · Return on capital: 71.6% · Combined rank: 17
· Cash Flow (FCF) — Latest FCF: $246.4M · FCF yield: 10.4% · Positive FCF years: 3
· Deep Value (Templeton) — P/E: 12.47 · P/B: 1.26 · Latest EPS: 3.91 · Dividend yield: 0.0%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.24 · Operating cash flow: $257.6M · Net income: $190.3M
· Shareholder Yield — Shareholder yield: 6.6% · of which dividends: 0.0% · of which buybacks: 6.6%
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold PBH — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 14, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
| Aug 6, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on PBH
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.